Boston Scientific Corporation (BSX - Free Report) recently announced positive results from the first clinical trial on the HeartLogic Heart Failure Diagnostic Service to evaluate impending heart failure (HF) decompensation. Data collected from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study were presented as a late-breaking clinical trial at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans.
The study included 900 patients who had improved sensor data collection enabled in their cardiac resynchronization therapy defibrillator (CRT-D) systems and were followed for up to one year in either a development or test cohort. Information from the 500 patients within the development set was used to construct the HeartLogic composite index and alert algorithm by combining heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity. The 400 patients within the test set were sequestered for subsequent independent validation of HeartLogic.
The MultiSENSE trial data confirmed that HeartLogic alert had an observed sensitivity of 70% and a low unexplained alert rate (alerts not followed by a HF event) of 1.47 per patient per year. The data also demonstrated that the alert algorithm by combining multiple measurements could successfully inform clinicians of worsening heart failure and lay the foundation for future studies.
Notably, HeartLogic Heart Failure Diagnostic Service is not commercially available at present. Management has submitted a design profile for CE Mark and a premarket FDA approval application of the HeartLogic service and plans to carry out post-approval studies, including Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF), to further evaluate the alert. We expect this latest development to advance this process of approval.
As per a GlobalData report, the global heart failure market is set to grow to $11.8 billion by 2025, at a CAGR of 13.7%. We believe Boston Scientific has the means to cash in the opportunities in this growing market. In its recently concluded third quarter, Boston Scientific’s Medsurg and Rhythm Management segment posted a strong performance, recording a 10% growth. The HeartLogic service study results will boost the segment’s capabilities to develop differentiated solutions for the management of heart failure cases.
Zacks Rank & Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are NxStage Medical Inc. (NXTM - Free Report) , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation (BVX - Free Report) . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy) while Bovie Medical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
NxStage Medical surged 31.6% over the last one year compared to the S&P 500’s 6.3% over the same period. The company has a four-quarter average positive earnings surprise of 50.00%.
Baxter International rallied 20.9% in the past one year, much higher than the S&P 500’s 4.5%. It has a trailing four-quarter average positive earnings surprise of 27%.
Bovie Medical recorded a 126.5% gain in the past one year, way better than the S&P 500’s 4.5%. The company has a trailing four-quarter positive average earnings surprise of 28.7%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>